Principal Display Panel (Xeloda 500mg(roche))
.jpg)
Xeloda
Product Images NDC 53808-0411
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Xeloda (NDC 53808-0411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Xeloda 01)
Figure (Xeloda 02)
Figure (Xeloda 03)
Figure (Xeloda 04)
Figure (Xeloda 05)
Figure (Xeloda 06)
This appears to be a graphical representation of estimated probabilities, with time and dosage information for two drugs: Docelanel and Yeloda. The time axis ranges from 0 to 800 days, and the Y-axis includes estimated probabilities ranging from 0.08 to 0.10. The dosage information for Docelanel is 100mg/sam/3 weeks while for Yeloda it is 1250 {roq/ e fuice doly) inarmitfent w/docelael 75 (ma/sam /3 weska).*
Figure (Xeloda 07)
This text is a warning about the side effects of a drug called XELODA (capecitabine) tablets. It advises patients to stop taking the medication immediately and contact their doctor if they experience symptoms such as moderate diarrhea, pain and redness of the mouth, swelling of the mouth, dark urine, fever, nausea, vomiting, and pain, swelling, and redness in the hands or feet. The text also notes that most side effects will improve after stopping the medication. Patients are advised to call their doctor again if symptoms do not improve within 2 or 3 days and to consult their doctor before starting XELODA again or adjusting the dosage.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
